These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 19276272)

  • 1. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial design for evaluation of novel targeted therapies.
    Farley J; Rose PG
    Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
    Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate endpoints for screening phase II studies.
    Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
    Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.